Article Text

Download PDFPDF

P012 First multicenter evaluation of initial experience and short-term follow-up of cerebral aneurysms treated with the Trenza Embolization device
Free
  1. Marcel Wolf1,
  2. Ahmed Othman1,
  3. Luca Valvassori2,
  4. Riitta Rautio3,
  5. Höltje Jan4,
  6. Ivan Jovanovic5,
  7. David Ozretic5,
  8. Luca Allegretti6,
  9. Jan-Hendrik Buhk7,
  10. Marielle Sophie Ernst8,
  11. Marc Brockmann1
  1. 1Department of Neuroradiology, University Medical Center Mainz, Mainz, Germany
  2. 2Department of Neuroradiology, ASST Santi Paolo E Carlo, Milan, Italy
  3. 3Department of Interventional Radiology, Turku University Hospital, Turku, Finland
  4. 4Department of Neuroradiology, University Medical Center Schleswig-Holstein, Lübeck
  5. 5Department of Diagnostic and Interventional Neuroradiology, School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia
  6. 6Department of Neuroradiology, Santa Corona Hospital, Pietra Ligure, Italy
  7. 7Neuroradiology, Asklepios Hospitals St. Georg, Hamburg, Germany
  8. 8Department of Diagnostic and Interventional Neuroradiology, University Medical Center Goettingen, Goettingen, Germany

Abstract

Introduction Intrasaccular devices are an increasingly recognized option in endovascular therapy of cerebral aneurysms, in particular in wide-necked and ruptured aneurysms. The Trenza Embolization Device (TED) is a novel intrasaccular device. Literature about TED is scarce, as the prospective post-market multicenter study TREAT is currently still recruiting.

Aim of Study To evaluate first experience and short-term follow-up (FU) of the novel TED in the therapy of cerebral aneurysms.

Methods Retrospective multicenter analysis of 25 aneurysms (3 ruptured) in 25 patients (18 females, mean age 62.4 years) treated with TED. Succesful deployment of the device, necessity of adjunct devices, complications, occlusion according to Raymond-Roy occlusion classification (RROC), initially and at first FU after treatment were evaluated.

Results Initial selected TED was successfully implanted in 24/25 (96%) cases. In 6/25 (24%) aneurysms two TED were implanted. In two (8%) cases adjunct devices were necessary, in one case stent-assistance, and in another both balloon- and stent-assistance. Except symptomatic thrombembolic event in one (4%) case, no further relevant complications were observed. Initial occlusion was RROC I in 12 (48%), and RROC II in 13 (52%) cases. In 17 cases FU (mean 6, range 3-11 months) was available, showing occlusion RROC I, and RROC II in each 8 (47%) cases, while one aneurysm (6%) with initially RROC II showed relevant reperfusion (RROC III) with indication to re-therapy.

Conclusion The results of this first retrospective, multicenter analysis of the novel TED appear promising. Further prospective, multicenter studies with larger patient cohorts, and long-term FU are neccessary.

Disclosure of Interest no.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.